Results 261 to 270 of about 60,986 (304)

Characterizing the Emergence of Myeloid-Derived Suppressor Cell Subsets in a Murine Model of Pulmonary Fibrosis. [PDF]

FASEB J
Vedder N, Gercke P, Lautenschlager N, Brunn T, Lange T, Schieb J, Vetter C, van Geffen C, Kolahian S.   +8 more
europepmc   +1 more source

Adoptive Transfer of Lepr⁺ Bone Marrow Cells Attenuates the Osteopetrotic Phenotype of <i>db</i>/<i>db</i> Mice. [PDF]

Int J Mol Sci
Turner RT, Wong CP, Philbrick KA, Keune JA, Labut EM, Menn SA, Branscum AJ, Iwaniec UT.   +7 more
europepmc   +1 more source

CRISPR antiviral inhibits neurotrophic JC polyomavirus in 2D and 3D culture models through dual-gRNA excision by SaCas9. [PDF]

Mol Ther Nucleic Acids
Rocchi A, Liao S, Liu H, Chen C, Çakır S, Bellizzi A, Wollebo HS, Sariyer IK, Khalili K.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Adoptive T-cell Transfer in Melanoma

Immunotherapy, 2012
Immunotherapy holds a highly promising treatment approach for metastatic melanoma patients. Adoptive cell transfer (ACT) involves the ex vivo expansion of autologous antitumor reactive lymphocytes and their reinfusion into lymphodepleted patients, accompanied by IL-2 administration.
Jacob Schachter, Dragoslav Zikich, Gal Markel, Gal Markel, Orit Itzhaki, Daphna Levy, Michal J. Besser, Avraham J. Treves   +7 more
openaire   +3 more sources

Adoptive transfer of T-cell immunity

Trends in Immunology, 2002
Abstract Allogeneic transplantation is the most successful form of T-cell-based cancer immunotherapy to date. However, a major complication of allogeneic transplantation remains the occurrence of graft-versus-host disease (GVHD). Two recent developments might lead to procedures for the induction of strong tumor-specific T-cell immunity without these ...
Monika C. Wolkers, Ton N. Schumacher, Helmut W. H. G. Kessels   +2 more
openaire   +3 more sources

Adoptive T‐cell transfer in cancer immunotherapy

Immunology & Cell Biology, 2006
Adoptive T‐cell therapy has definite clinical benefit in relapsed leukaemia after allogeneic transplant and in Epstein–Barr virus‐associated post‐transplant lymphoproliferative disease. However, the majority of tumour targets are weakly immunogenic self‐antigens and success has been limited in part by inadequate persistence and expansion of transferred
Tey, Siok-Keen, Bollard, Catherine M., Heslop, Helen E.   +2 more
openaire   +4 more sources

Adoptive cell transfer therapy for melanoma

Experimental Dermatology, 2022
AbstractAdoptive cell transfer (ACT) of tumor‐infiltrating lymphocytes (TILs) for melanoma is an example of the most successful cancer immune therapy. It achieves a durable complete response about ~20% of patients, and they might be cured. However, the ratio of patients with durable benefits is not high, and its complicated procedure prevents its ...
openaire   +2 more sources

Transiently redirected T cells for adoptive transfer

Cytotherapy, 2011
T cells can be redirected to reject cancer by retroviral transduction with a chimeric antigen receptor (CAR) or by administration of a bispecific T cell engager (BiTE). We demonstrate that transfection of T cells with messenger (m) RNA coding for CAR is an alternative strategy.We describe the pre-clinical evaluation of a method based on transient ...
Gustav Gaudernack, Gustav Gaudernack, Hilde Almåsbak, Hanna Julie Hoel, Martin Pule, Gunnar Kvalheim, Anne Marie Rasmussen, Edith Rian, Séébastien Wälchli   +8 more
openaire   +3 more sources

Adoptive T Cell Transfer

2012
The clinical use of adoptively-transferred T or NK lymphocytes with anti-tumor activity is gaining in popularity as reports of success accumulate. High specific activity with minimal off target effects contribute to a class of therapy with minimal toxicity that is transformative for cancer patients, who with their physicians have come to accept severe ...
Conrad Russell Y. Cruz, Donald R. Shaffer, Cliona M. Rooney   +2 more
openaire   +2 more sources

T-cell–based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition [PDF]

Cancer Immunology Research, 2015
Abstract Tumor immunotherapy has had demonstrable efficacy in patients with cancer. The most promising results have been with T-cell–based therapies. These include adoptive cell transfer of tumor-infiltrating lymphocytes, genetically engineered T cells, and immune checkpoint inhibitor antibodies. In this review, we describe the different
Houot, Roch, Schultz, Liora Michal, Marabelle, Aurelien, Kohrt, Holbrook   +3 more
openaire   +2 more sources